CTRI/2022/10/046396尚未招募未知
ow dose methylprednisolone in early mild-moderate ARDS in burn patients: A single centre open label randomised control trial
AIIMS New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients aged 18-65 years with severe burns (more than 20% total body surface area excluding areas of superficial burn) with early (within 72 hrs of onset) mild to moderate ARDS according to definition by Berlinââ?¬•s criteria (p/f ratios 150 to ââ?°Â¤ 300) within 10 days history of burns
排除标准
- •a) Age <18 years and >65 years
- •b) Patients with p/f ratios <150
- •c) Burns < 205 total body surface area
- •d) Moribund state (i.e., not expected to survive more than 24 hr)
- •e) Advanced malignancy with life expectancy <6 months
- •f) Pregnancy
- •g) Patients on immunosuppressive therapy
研究者
相似试验
招募中
不适用
Optimal Dosage of Methylprednisolone in the Treatment of Geriatric Sudden Hearing Loss: A Propensity Score-matched AnalysisDiseases of the ear and mastoid processKCT0001066Eulji University Hospital109
进行中（未招募）
不适用
Phase II Study of High-dose Methylprednisolone and Rituximab in Previously Treated Patients with High Risk Chronic B Lymphocytic Leukemia - High-dose Methylprednisolone and Rituximab in High Risk B-CEUCTR2007-001818-16-LTVilnius University Hospital Santariskiu Clinics50
招募中
2 期
ow dose versus moderate dose Prednisolone in Acute CPPDAcute CPPD attackCPPD attackTCTR20211224003FACULTY OF MEDICINE VAJIRA HOSPITA73
已完成
2 期
Effect of Methylprednisolone in treatment of COVID-19 patientsthe 2019 novel Corona virus (COVID-19).COVID-19 confirmed by laboratory testing.U07.1IRCT20200204046369N1Shiraz University of Medical Sciences82
进行中（未招募）
不适用
Randomized study with methylprednisolone 1mg/kg/day for treatment of grade I acute GvHDpatients developing acute GvHD grade IMedDRA version: 14.1Level: LLTClassification code 10000802Term: Acute GVH diseaseSystem Organ Class: 100000004870EUCTR2008-000413-29-ITGITMO GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO,CELLULE STAMINALI EMOPOIETICHE E TERAPIA CELLULARE - ONLUS